ReviewiLIVER2022
Radiomics/Radiogenomics in hepatocellular carcinoma: Applications and challenges in interventional management.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CT-Based Radiomics for Non-Invasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Multiphase MRI radiomics model for predicting microvascular invasion in HCC: Development and clinical validation.iLIVER · 2025Article
- Development and External Validation of a Combined Clinical-Radiomic Model for Predicting Insufficient Hypertrophy of the Future Liver Remnant following Portal Vein Embolization.Annals of surgical oncology · 2025Article
- A radiomics nomogram based on MSCT and clinical factors can stratify fibrosis in inflammatory bowel disease.Scientific reports · 2024Article
- Article
- Hepatocellular carcinoma: State of the art diagnostic imaging.World journal of radiology · 2023Review
- Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews.Journal of hepatocellular carcinoma · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Recently, radiomics and radiogenomics have been introduced as novel dimensions in oncology research. In the current review, we summarize the clinical applications of radiomics and radiogenomics in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.